Analyst consensus rating
LENZ Therapeutics Analyst Rating: Buy
Direct answer
LENZ Therapeutics's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.00.
Forecast evidence checked October 27, 2026.
Get free LENZ Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.15
- Average price target
- $20.00
- High price target
- $50.00
- Low price target
- $5.00
- Low target gap
- +58.7%
- Target upside
- +534.9%
- High target gap
- +1,487.3%
- Target range width
- 1,428.6%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for LENZ Therapeutics?
LENZ Therapeutics has a verified Buy consensus. The same dataset has an average price target of $20.00.
How far are LENZ Therapeutics's low and high targets from the recorded price?
The low target implies +58.7%, while the high target implies +1,487.3%.
How many analysts are included in LENZ Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is LENZ Therapeutics's target upside or downside calculated?
The average target of $20.00 is divided by the recorded price of $3.15, then one is subtracted to produce +534.9%. This does not guarantee a future return.
When was LENZ Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.